Olezarsen

Locations: 🇪🇸
Hospital Universitario de Jaen, Jaén, Spain
🇪🇸
Hospital Abente y Lago, La Coruna, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

and more 251 locations

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Phase 3

Active, not recruiting

Conditions: Cardiovascular Diseases
Hypertriglyceridemia
Atherosclerosis

Interventions: Drug: Placebo
Drug: Olezarsen

First Posted Date: 2022-11-09

Last Posted Date: 2025-04-09

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 1478

Registration Number: NCT05610280

Locations: 🇮🇹
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome, Italy
🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇵🇱
FutureMeds Sp. z o.o, Wrocław, Poland

and more 163 locations

A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Olezarsen

First Posted Date: 2022-10-14

Last Posted Date: 2024-05-10

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 104

Registration Number: NCT05579860

Locations: 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Phase 3

Active, not recruiting

Conditions: Severe Hypertriglyceridemia

Interventions: Drug: Placebo
Drug: Olezarsen

First Posted Date: 2022-09-23

Last Posted Date: 2025-01-29

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 446

Registration Number: NCT05552326

Locations: 🇺🇸
Clinical Investigation Specialists Inc., Kenosha, Wisconsin, United States
🇺🇸
NRC Research Institute, Los Angeles, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 199 locations

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Phase 2

Completed

Conditions: Hypertriglyceridemia
Atherosclerotic Cardiovascular Disease
Severe Hypertriglyceridemia

Interventions: Drug: Olezarsen
Drug: Placebo

First Posted Date: 2022-05-02

Last Posted Date: 2024-11-27

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 154

Registration Number: NCT05355402

Locations: 🇺🇸
Main Street Physicians Care Waterway, Little River, South Carolina, United States
🇨🇦
Ecogene-21, Chicoutimi, Quebec, Canada
🇨🇦
Clinique des Maladies Lipidiques de Quebec Inc., Quebec, Canada

and more 21 locations

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

Phase 3

Active, not recruiting

Conditions: Familial Chylomicronemia Syndrome

Interventions: Drug: Olezarsen

First Posted Date: 2022-01-11

Last Posted Date: 2024-12-04

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT05185843

Locations: 🇨🇦
Ecogene-21, Chicoutimi, Quebec, Canada
🇨🇦
Centre Hospitalier Universite de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada
🇺🇸
Diabetes/Lipid Management & Research Center, Huntington Beach, California, United States

and more 8 locations

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Phase 3

Active, not recruiting

Conditions: Familial Chylomicronemia Syndrome

Interventions: Drug: Olezarsen

First Posted Date: 2021-11-23

Last Posted Date: 2025-03-04

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT05130450

Locations: 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇺🇸
University of Kansas Medical Center (KUMC), Kansas City, Kansas, United States
🇺🇸
IDS Central, Philadelphia, Pennsylvania, United States

and more 24 locations

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Phase 3

Active, not recruiting

Conditions: Severe Hypertriglyceridemia

Interventions: Drug: Olezarsen
Drug: Placebo

First Posted Date: 2021-10-15

Last Posted Date: 2025-01-29

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 617

Registration Number: NCT05079919

Locations: 🇺🇸
Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
🇿🇦
Dr Jan Engelbrecht and Ass. Inc, Cape Town, Western Cape, South Africa
🇳🇱
Albert Schweitzer ziekenhuis, Dordrecht, Netherlands

and more 198 locations

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

Phase 3

Completed

Conditions: Familial Chylomicronemia Syndrome

Interventions: Drug: Placebo
Drug: Olezarsen

First Posted Date: 2020-09-29

Last Posted Date: 2025-03-06

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 66

Registration Number: NCT04568434

Locations: 🇵🇹
Hospital da Senhora da Oliveira - Guimaraes, Creixomil, Portugal
🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇳🇴
The Lipid Clinic (Oslo University Hospital), Oslo, Norway

and more 44 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy